Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the prostate
• * Stage T1a, T1b, T1c disease
• * Stage T2a or T2b
• No direct evidence of regional or distant metastases
• No T2c, T3, or T4 tumors
• Gleason score ≤ 7
• Must meet the following criteria:
• * Prostate-specific antigen (PSA) ≤ 20 ng/mL prior to starting hormonal therapy (if given) for patients with a Gleason score of 2-6
• * PSA ≤ 15 ng/mL prior to starting hormonal therapy (if given) for patients with a Gleason score of 7
• * Risk of pelvic lymph node involvement \< 20% according to Roach formula
• Ultrasound-based volume estimation of the prostate gland ≤ 60 g
• PATIENT CHARACTERISTICS:
• Zubrod performance status 0-2
• Fertile patients must use effective contraception
• No prior invasive malignancy, except for nonmelanoma skin cancer, unless disease-free for a minimum of 3 years (e.g., carcinoma in situ of the breast, oral cavity, or cervix are allowed)
• No significant urinary obstructive symptoms
• * American Urological Association (AUA) score of ≤ 15 (alpha blockers allowed)
• No history of inflammatory colitis (including Crohn disease and ulcerative colitis)
• No history of significant psychiatric illness
• No severe, active comorbidity including any of the following:
• * Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
• * Transmural myocardial infarction within the past 6 months
• * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
• * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration
• * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
• * Laboratory tests for liver function and coagulation parameters are not required for entry into this protocol
• * AIDS (based on current CDC definition) or other immunocompromising condition
• * HIV testing is not required for entry into this protocol
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• More than 9 months since prior hormonal therapy as neoadjuvant therapy or to downsize the prostate gland
• No prior pelvic radiotherapy
• No prior chemotherapy or surgery for prostate cancer
• No prior transurethral resection of the prostate (TURP) or cryotherapy to the prostate
• No plans for other concurrent post-treatment, adjuvant, antineoplastic therapy including surgery, cryotherapy, conventionally fractionated radiotherapy, hormonal therapy, or chemotherapy as part of the treatment for prostate cancer